CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 51 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Oxytocin 40 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03060031
NCT03060031Phase 1Completed
CompareCT.gov

Effects of Oxytocin Administration on Social Influence Effects on Pain

University of Colorado, Boulder·interventional·Posted Feb 23, 2017·Updated Jun 25, 2019

In Brief

A Phase 1 clinical trial evaluating Oxytocin and Placebo for Pain. Completed, enrolled 51 participants across 1 site.

Detailed Summary

This experiment will explore the joint effects of social information, social support, associative learning, and oxytocin on the development of placebo analgesia. The investigators predict that socially transmitted placebo effects will be enhanced by nasal administration of oxytocin, whereas associative learning effects on pain will not be altered by this pharmacological manipulation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 23, 2017
Enrollment StartJun 21, 2017
Primary CompletionMar 5, 2019
Study CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.4 years ago

Interventions

Oxytocindrug

Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.

Placebodrug

Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks